ELVN20261218C12.5
ELVN Dec 18 2026 12.50 Call (ELVN261218C00012500)
option OPRA

enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.